Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3142 | Psychosocial stimulation and healthy eating education Wiki | 0.41 |
| drug2276 | Magnetic Resonance Spectroscopy (MRS). Wiki | 0.41 |
| drug2665 | Observational study only Wiki | 0.41 |
Navigate: Correlations HPO
There are 6 clinical trials
Covid-19 pandemic now affects more than two million people worldwide. The neurotropism of the virus is assumed by its frequent association with neurological symptoms (anosmia, ageusia, headaches) but the extent of the central or peripheral nervous system involvement and the associated symptomatology remain poorly known for now. The main objective of this study is to describe the neurological and psychiatric manifestations occurring in the context of Covid-19 infection in patients hospitalized or followed-up in the APHP.SU hospital group. A better understanding of the neuropsychiatric impairment related to Covid-19 would improve the management of these patients in the acute phase, and knowledge of subsequent complications would allow adapting their rehabilitation and follow-up. The precise phenomenological description of these manifestations and the imaging, biology and neuropathology data will be compiled from the data collected by the physicians in charge of these patients as part of their inpatient or outpatient care. This study will also allow collecting unusual clinical manifestations from patients followed for neurological or psychiatric pathology in hospital departments and presenting a Covid-19 infection, in order to optimize the reorganization of their management, follow-up and rehabilitation in the epidemic context.
Description: Frequency of central or peripheral neurological or psychiatric symptoms observed in patients with COVID-19
Measure: Central or peripheral neurological symptoms or psychiatric symptoms observed in patients with Covid-19 Time: 12 monthsDescription: Impact on neurological or psychiatric disease trajectories assessed by severity scores or subjective progression (improved, stable, impaired) during and after COVID-19 pathology in patients with pre-existing neurological and psychiatric diseases
Measure: Progression of pre-existing neurological or psychiatric pathologies Time: 12 monthsThis is a multicenter, multinational observational cohort study to document neurologic manifestations of COVID 19 among pediatric patients requiring hospital admission for confirmed or suspected COVID 19 (Coronavirus 19 disease, caused by infection with the SARS-CoV-2 (acute respiratory syndrome 2 ) virus. SARS-CoV2 shares significant structural and biological similarities with SARS-CoV including using the ACE-2 receptor as a docking site, a property that confers neurotropism. This study is sponsored and led by members of the Pediatric Neurocritical Care Research Group (PNCRG).
Description: Chart review
Measure: Frequency of neurologic manifestations of COVID 19 among pediatric patients requiring hospital admission for confirmed or presumed COVID 19 Time: From date of hospital admission until the date of hospital discharge (including death), assessed up to 12 monthsDescription: Chart Review
Measure: Associations between prescription of empiric COVID-19 directed therapies and patient characteristics and outcomes among children with or without neurologic manifestations and confirmed or presumed COVID-19 Time: From date of hospital admission until the date of hospital discharge (including death), assessed up to 12 monthsThis study will determine the neurological profile and predictors of outcomes in patients with COVID-19 disease in the Philippines. It will also evaluate if there is significant difference between COVID-19 patients with neurological manifestations compared to those COVID-19 patients without neurological manifestations in terms of various prespecified clinical outcomes. Furthermore, the likelihood of these outcomes in COVID-19 patients with neurological manifestations compared to those without neurological manifestation will be determined in this study.
Description: Defined as patients with confirmed COVID-19 who died
Measure: Mortality (binary outcome) Time: from admission until occurrence of mortality, assessed up to 6 monthsDescription: Defined as the patient with confirmed COVID-19 who experienced clinical symptoms and signs of respiratory insufficiency. Clinically, this condition may manifest as tachypnea, abnormal blood gases (hypoxemia or hypercapnia), signs of increased work of breathing, and requires oxygen supplementation
Measure: Respiratory failure (binary outcome) Time: from admission until occurrence of respiratory failure, assessed up to 6 monthsDescription: Defined as the number of days from initiation of assisted ventilation to extubation
Measure: Duration of ventilator dependence (continuous outcome) Time: day of intubation to day of extubation, assessed up to 6 monthsDescription: Defined as the patients with confirmed COVID-19 who are admitted to an ICU or ICU-comparable setting
Measure: Intensive care unit (ICU) admission (binary outcome) Time: admission to ICU admission, assessed up to 6 monthsDescription: Defined as the number of days admitted in the ICU or ICU-comparable setting
Measure: Length of ICU stay (continuous outcome) Time: ICU admission to ICU discharge, assessed up to 6 monthsDescription: Defined as the number of days from admission to discharge
Measure: Length of hospital stay (continuous outcome) Time: admission to hospital discharge, assessed up to 6 monthsThis study is a prospective observational cohort study to document the prevalence and types of neurological manifestations among hospitalized patients with confirmed or suspected novel coronavirus infection (COVID-19).
Description: Proportion of patients with neurological symptoms out of all hospitalized COVID19 patients during study period.
Measure: Prevalence of neurological manifestations Time: During hospital course, up to 1 monthDescription: Patients will be assessed on a scale score of 0 (no symptoms at all) to 5 (severe disability; bedridden, incontinent and requiring constant nursing care and attention)
Measure: Global functional outcomes using modified Rankin score Time: At hospital discharge, approximately 1 monthViral pandemics, such as HIV and SARS-Cov-V1, have shown that they can lead to acute and / or delayed neurological complications. At the actual context of the pandemic Coronavirus disease 2019 (COVID-19), neurological manifestations seem to be confirmed since in 85% of COVID-19 patients, present neurological symptoms, including anosmia, ageusia, periorbital pain, dizziness, fatigue, even moderate headache, moderate memory and/or behavioral disorders. However, these neurological manifestations are not well studied and their radiological features are not well described. It is therefore important to assess these potential neurological complications in COVID-19 patients. To the investigator knowledge, there is no previous study in the literature describing spectral brain changes in COVID + patients. Thus, the goal of this work is to describe the radiological semiology using MRI and particularly Magnetic Resonance Spectroscopic (MRS) biomarkers in the evaluation of acute and / or delayed brain damage in COVID + patients presenting a neurological manifestations that are initially related to the cranial nerves damage.
Description: The radiological semiology as described by MRI and particularly Magnetic Resonance Spectroscopic (MRS) biomarkers in the COVID-19 patients presenting neurological manifestations related initially to the cranial nerves damage.
Measure: Variation from baseline of MRI radiological semiology in COVID-19 patients Time: 9 months after patient inclusionPatients with neurological or psychiatric symptoms or pre-existing disease will be sampled (blood for serum and DNA or saliva for DNA) at inclusion and at M6 (blood) and M12 (blood) depending on their pathology. Sampling will be done either at hospital if patient is on site for routine care or at home if no consultation is scheduled at hospital.
Description: dosage of seric markers (anti-SARS-CoV2 IgG) or genetic markers (genetic variants) observed during COVID 19 infection in patients
Measure: dosage of seric markers (anti-SARS-CoV2 IgG) or genetic markers (genetic variants) observed during COVID 19 infection in patients Time: 12 monthsDescription: Neurodegenerative markers (e.g., neurofilaments) associated with a neurological or psychiatric manifestation of Covid-19 infection
Measure: Serum neurofilaments Time: 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports